The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
Public ClinicalTrials.gov record NCT03092102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects
Study identification
- NCT ID
- NCT03092102
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 136 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 19, 2017
- Primary completion
- Feb 24, 2019
- Completion
- Feb 24, 2019
- Last update posted
- Jul 26, 2020
2017 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Covance Clinical Research Unit, Inc. | Madison | Wisconsin | 35756 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Idiopathic Pulmonary Fibrosis trials
Other public records listing Idiopathic Pulmonary Fibrosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT06325696: H01 in Adults With Interstitial Lung Disease (The SOLIS Study) Recruiting
- NCT05389215: Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF Active, not recruiting
- NCT07671911: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets Recruiting
- NCT07674745: Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Not yet recruiting
- NCT05241275: Xenon MRI and Progressive ILD Active, not recruiting
- NCT00470327: A Study of the Natural Progression of Interstitial Lung Disease (ILD) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03092102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2020 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03092102 live on ClinicalTrials.gov.